Nifty
:
24426.85
Sensex
:
79809.65
-74.05 (-0.30%)
-270.92 (-0.34%)
Nifty
Sensex
:
:
24426.85
79809.65
-74.05 (-0.30%)
-270.92 (-0.34%)

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 524404 | NSE: MARKSANS

NSE BSE
168.60
29-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  170
  •  172.2
  •  166.75
  •  169.47
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1140151
  •  192956900.85
  •  358.7
  •  166.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,647.14
  • 21.84
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,966.01
  • 0.47%
  • 3.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.87%
  • 1.67%
  • 26.74%
  • FII
  • DII
  • Others
  • 19.89%
  • 3.55%
  • 4.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.37
  • 13.77
  • 12.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.85
  • 9.25
  • 9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.10
  • 10.03
  • 12.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.54
  • 15.05
  • 23.04

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.85
  • 3.22
  • 3.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.22
  • 11.05
  • 13.49

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
6.92
8.4
10.52
12.92
P/E Ratio
24.36
20.07
16.03
13.05
Revenue
2177
2623
3129
3708
EBITDA
459
529
652
792
Net Income
314
381
478
586
ROA
12.9
12.9
12.3
12.4
P/B Ratio
6.25
3.10
2.62
2.19
ROE
16.47
16.8
17.4
18
FCFF
47
65
294
449
FCFF Yield
0.43
0.59
2.68
4.09
Net Debt
-457
-383
-920
-1290
BVPS
26.98
54.44
64.4
77

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
619.99
590.62
4.97%
708.46
560.01
26.51%
681.85
586.13
16.33%
641.92
531.24
20.83%
Expenses
519.87
462.18
12.48%
582.70
450.37
29.38%
543.08
453.11
19.86%
506.24
417.29
21.32%
EBITDA
100.12
128.44
-22.05%
125.75
109.64
14.69%
138.76
133.02
4.32%
135.68
113.95
19.07%
EBIDTM
16.15%
21.75%
17.75%
19.58%
20.35%
22.70%
21.14%
21.45%
Other Income
5.64
14.95
-62.27%
16.52
16.53
-0.06%
27.85
4.80
480.21%
11.06
19.00
-41.79%
Interest
6.06
2.92
107.53%
3.44
4.84
-28.93%
2.67
3.16
-15.51%
2.63
1.63
61.35%
Depreciation
23.10
20.44
13.01%
22.74
21.05
8.03%
20.69
22.00
-5.95%
19.51
17.55
11.17%
PBT
76.60
120.02
-36.18%
116.09
100.28
15.77%
143.26
112.66
27.16%
124.60
113.77
9.52%
Tax
18.40
30.95
-40.55%
25.37
22.63
12.11%
38.19
29.69
28.63%
26.84
29.92
-10.29%
PAT
58.20
89.07
-34.66%
90.73
77.64
16.86%
105.07
82.97
26.64%
97.76
83.85
16.59%
PATM
9.39%
15.08%
12.81%
13.86%
15.41%
14.15%
15.23%
15.78%
EPS
1.29
1.96
-34.18%
2.00
1.73
15.61%
2.31
1.84
25.54%
2.13
1.84
15.76%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
2,652.22
2,622.84
2,177.41
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
Net Sales Growth
16.94%
20.46%
17.56%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
 
Cost Of Goods Sold
1,143.78
1,143.74
1,038.12
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
Gross Profit
1,508.44
1,479.10
1,139.29
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
GP Margin
56.87%
56.39%
52.32%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
Total Expenditure
2,151.89
2,094.21
1,718.83
1,512.82
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
Power & Fuel Cost
-
40.08
36.94
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
% Of Sales
-
1.53%
1.70%
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
Employee Cost
-
350.30
293.64
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
% Of Sales
-
13.36%
13.49%
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
Manufacturing Exp.
-
140.08
94.76
96.47
12.73
127.47
113.32
77.14
59.90
47.34
50.44
% Of Sales
-
5.34%
4.35%
5.21%
0.85%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
General & Admin Exp.
-
117.60
93.90
52.79
37.74
50.67
45.52
51.03
42.51
37.52
36.01
% Of Sales
-
4.48%
4.31%
2.85%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
Selling & Distn. Exp.
-
256.64
127.31
133.19
119.05
33.54
32.15
68.36
49.14
27.66
29.77
% Of Sales
-
9.78%
5.85%
7.19%
7.99%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
Miscellaneous Exp.
-
45.77
34.16
45.14
106.73
16.10
0.34
-0.01
0.05
0.00
29.77
% Of Sales
-
1.75%
1.57%
2.44%
7.16%
1.17%
0.03%
0.00%
0.01%
0%
0%
EBITDA
500.31
528.63
458.58
339.32
258.88
339.60
192.25
132.15
78.38
32.92
132.42
EBITDA Margin
18.86%
20.15%
21.06%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
Other Income
61.07
70.38
50.42
59.31
41.85
6.69
0.33
4.62
8.47
18.85
12.72
Interest
14.80
11.66
11.20
9.13
8.45
7.99
8.75
9.66
10.22
6.78
10.16
Depreciation
86.04
83.39
74.27
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
PBT
460.55
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Tax
108.80
121.35
108.63
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
Tax Rate
23.62%
24.08%
25.65%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
PAT
351.76
380.58
313.69
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
PAT before Minority Interest
350.16
382.62
314.89
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
Minority Interest
-1.60
-2.04
-1.20
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
PAT Margin
13.26%
14.51%
14.41%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
PAT Growth
5.47%
21.32%
17.79%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
 
EPS
7.76
8.40
6.92
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,466.91
2,065.05
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
Share Capital
45.32
45.32
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
Total Reserves
2,421.60
2,019.74
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
Non-Current Liabilities
272.91
205.20
84.33
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.92
4.56
3.25
1.86
2.11
1.47
1.36
1.08
0.96
0.00
Current Liabilities
477.34
389.85
340.99
380.08
298.97
228.75
232.62
234.68
296.06
259.43
Trade Payables
305.70
268.28
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
Other Current Liabilities
117.17
70.62
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
Short Term Borrowings
23.09
29.09
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
Short Term Provisions
31.39
21.86
26.60
41.92
31.88
40.72
5.74
29.36
23.85
51.88
Total Liabilities
3,239.63
2,680.95
2,190.39
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
Net Block
981.96
775.94
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
Gross Block
1,413.02
1,134.80
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
Accumulated Depreciation
431.06
358.87
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
Non Current Assets
1,035.51
818.46
515.09
435.04
325.20
308.45
271.02
280.19
267.92
280.06
Capital Work in Progress
27.11
9.42
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
26.27
32.94
18.91
4.16
4.16
5.73
1.29
0.82
0.59
10.41
Other Non Current Assets
0.17
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
2,204.12
1,862.49
1,675.30
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
Current Investments
0.74
26.99
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
Inventories
845.52
617.94
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
Sundry Debtors
540.04
453.18
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
Cash & Bank
704.21
673.58
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
Other Current Assets
113.61
30.98
22.74
24.36
14.11
14.66
28.06
15.63
21.05
19.76
Short Term Loans & Adv.
81.20
59.82
35.48
31.79
0.00
3.40
0.00
0.00
20.96
19.76
Net Current Assets
1,726.78
1,472.64
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
Total Assets
3,239.63
2,680.95
2,190.39
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
206.66
230.41
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
PBT
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Adjustment
69.37
55.42
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
Changes in Working Capital
-240.77
-126.19
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
Cash after chg. in Working capital
332.56
352.76
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-125.90
-122.35
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-49.01
-140.84
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
Net Fixed Assets
-141.06
-91.31
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
Net Investments
26.25
-26.45
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
Others
65.80
-23.08
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
Cash from Financing Activity
-65.15
-68.73
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
Net Cash Inflow / Outflow
92.51
20.84
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
Opening Cash & Equivalents
403.28
382.44
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
Closing Cash & Equivalent
495.79
403.28
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
54.44
45.57
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
ROA
12.93%
12.93%
13.78%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
ROE
16.89%
16.53%
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
ROCE
22.50%
22.40%
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
Fixed Asset Turnover
2.16
2.33
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
Receivable days
65.99
69.35
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
Inventory Days
97.24
87.89
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
Payable days
91.59
87.70
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
Cash Conversion Cycle
71.65
69.54
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
Total Debt/Equity
0.01
0.01
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
Interest Cover
44.22
38.80
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Marksans Pharma’s arm receives marketing authorization from UK MHRA
    18th Aug 2025, 14:25 PM

    Relonchem has received marketing authorization for Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets

    Read More
  • Marksans Pharma - Quarterly Results
    12th Aug 2025, 13:46 PM

    Read More
  • Marksans Pharma’s arm gets approval from USFDA for Omeprazole Delayed-Release Tablets
    8th Aug 2025, 12:41 PM

    Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach

    Read More
  • Marksans Pharma’s arm gets EIR from USFDA for New York facility
    30th Jun 2025, 16:12 PM

    Current Good Manufacturing Practices inspection was conducted by the USFDA from April 16, 2025 to April 24, 2025

    Read More
  • Marksans Pharma’s arm gets marketing authorization for Oxybutynin hydrochloride
    19th Jun 2025, 10:41 AM

    Relonchem has received Marketing Authorization from UK Medicines & Healthcare Products Regulatory Agency

    Read More
  • Marksans Pharma’s arm gets marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution
    30th May 2025, 10:41 AM

    Relonchem has received marketing authorization from UK Medicines & Healthcare Products Regulatory Agency

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.